Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151657 | 0.91 | HRH3 (0.40) | HRH3TSHRALDH1A1 | |
| SCHEMBL6267484 | 0.88 | NPC1 (0.41) | — | |
| SCHEMBL9705589 | 0.86 | TRPA1 (0.43) | HRH3LTA4HTSHRTRPA1ALDH1A1 | |
| SCHEMBL9705573 | 0.84 | KCNA3 (0.50) | HRH3 | |
| SCHEMBL5636691 | 0.83 | KCNA3 (0.46) | LTA4HALDH1A1 | |
| SCHEMBL9705568 | 0.82 | KCNA3 (0.48) | — | |
| SCHEMBL9539656 | 0.82 | KCNA3 (0.48) | — | |
| SCHEMBL4150998 | 0.82 | HRH3 (0.39) | HRH3LTA4HTSHRALDH1A1CHKA | |
| SCHEMBL4086993 | 0.82 | TRPA1 (0.40) | HRH3LTA4HTSHRTRPA1ALDH1A1 | |
| SCHEMBL10614694 | 0.82 | KCNA3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8815934-B2 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815934-B2 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815934-B2 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1082319-A1 | BENZOCARBAZOL AND INDENOINOLE DERIVED ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1076558-A1 | 2-PHENYL-1-[-(2-AMINOETHOXY)-BENZYL -INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6159959-A | Combined estrogen and antiestrogen therapy | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6127404-A | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)INDOLE COMPOUNDS USEFUL AS ESTROGEN AGONISTS/ANTAGONISTS; OSTEOPOROSIS; ANTICHOLESTEROL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6107292-A | HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| US-6069153-A | HORMONE REPLACEMENT THERPAY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999059581-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999058524-A1 | BENZOCARBAZOLE AND INDENOINDOLE DERIVED ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | HRH3 2260/4885LTA4H 1507/4885TSHR 739/4885 |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | HRH3 2260/4885LTA4H 1507/4885TSHR 739/4885 |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | BRCA1, ESR2, PKD2 | HRH3 3868/4885LTA4H 3871/4885TSHR 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.